D017322Activities & BehaviorsProceduresE05.318.760.535.210E05.337.250.210N05.715.360.775.235.210N06.850.520.450.535.2109180.985115Clinical Trials, Phase II as TopicFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonDermatologyWake Forest School of MedicineDalaneKitzmanDalane W. Kitzman MD36.09003100000000-80.26802800000000228Kitzman, DalaneProfessorNancyKingNancy M. King JD36.09550200000000-80.24393700000000723King, NancyAssociate ProfessorStevenFeldmanSteven R. Feldman MD, PhD36.08959100000000-80.26859900000000884Feldman, StevenProfessor24218001Sorscher SThe oncologistSorscher S. Are targeted therapies a consideration in poorly differentiated neuroendocrine tumors? Oncologist. 2013; 18(11):1239.Oncologist2013-01-01T00:00:002013Are targeted therapies a consideration in poorly differentiated neuroendocrine tumors?28356300Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade MCirculation. Heart failureButler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. Circ Heart Fail. 2017 Apr; 10(4).Circ Heart Fail2017-04-01T00:00:002017Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.EmilyDresslerEmily V. Dressler PhD2117Dressler, EmilyAssociate ProfessorCaio MaxRocha LimaCaio Max S. Rocha Lima MD, MS2211Rocha Lima, Caio MaxProfessor29611211Liu M, Dressler EVStatistics in medicineLiu M, Dressler EV. A predictive probability interim design for phase II clinical trials with continuous endpoints. Stat Med. 2018 05 30; 37(12):1960-1972.Stat Med2018-04-02T00:00:002018A predictive probability interim design for phase II clinical trials with continuous endpoints.20Professor30451068Yan D, Wages NA, Dressler EVJournal of biopharmaceutical statisticsYan D, Wages NA, Dressler EV. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design. J Biopharm Stat. 2019; 29(2):333-347.J Biopharm Stat2018-11-17T00:00:002018Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.31264936Yan D, Tait C, Wages NA, Kindwall-Keller T, Dressler EVJournal of biopharmaceutical statisticsYan D, Tait C, Wages NA, Kindwall-Keller T, Dressler EV. Generalization of the time-to-event continual reassessment method to bivariate outcomes. J Biopharm Stat. 2019; 29(4):635-647.J Biopharm Stat2019-07-02T00:00:002019Generalization of the time-to-event continual reassessment method to bivariate outcomes.22Associate ProfessorInternal Medicine, Cardiovascular MedicineInternal Medicine, Hematology & OncologyPHS-Biostatistics and Data Science (Public Health Sciences)Surgery, Hypertensiontrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professor2.050020.01424029research area of0.7238410.048484832subject area for